• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Arch Otorhinolaryngol . Retronasal olfactory testing in early diagnosed and suspected COVID-19 patients: a 7-week follow-up study

tetano

Editor, Senior Moderator
Eur Arch Otorhinolaryngol


. 2021 May 13.
doi: 10.1007/s00405-021-06826-1. Online ahead of print.
Retronasal olfactory testing in early diagnosed and suspected COVID-19 patients: a 7-week follow-up study


Bernhard Prem[SUP] 1 [/SUP], David Tianxiang Liu[SUP] 1 [/SUP], Gerold Besser[SUP] 1 [/SUP], Bertold Renner[SUP] 2 3 [/SUP], Christian Albert Mueller[SUP] 4 [/SUP]



Affiliations

Abstract

Objectives: Olfactory dysfunction (OD) constitutes a major symptom in Coronavirus Disease 2019 (COVID-19). Yet, most data on smell loss rely on the evaluation of orthonasal olfactory performance. Therefore, we aimed to assess retronasal olfactory function (ROF) over a period of several weeks in proven and suspected COVID-19 patients.
Methods: One hundred and one subjects with suspected or laboratory-proven COVID-19 participated in this study. In patients with OD no longer than 4 weeks after initial symptom onset, ROF was measured with the 7-item Candy Smell Test ten times over 7 weeks.
Results: Olfactory function was decreased in the investigated patients and remained decreased over the course of 7 weeks. One-way repeated-measures ANOVA revealed no significant difference of ROF between different measurement time points. However, self-assessment of smell and flavour improved significantly (p = 0.013 and p = 0.043), but did not show complete recovery.
Conclusion: The current investigation revealed significant improvements in subjective smell and flavour perception over the course of 7 weeks in proven and suspected COVID-19 patients suffering from acute OD. However, objectively measured ROF based on a screening test revealed no improvements within the same time period.

Keywords: Anosmia; COVID-19; Flavor; Olfaction; Retronasal.
 
Back
Top Bottom